NET PROFIT (x1000 EUR)
EMPLOYEES
Enza Biotech AB
Closing information (x1000 EUR)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
0
|
0
|
0 |
| Earnings before taxes |
-802
|
-777
|
-763 |
| EBITDA |
-747
|
-721
|
-707 |
| Total assets |
499
|
495
|
571 |
| Current assets |
208
|
163
|
166 |
| Current liabilities |
160
|
93
|
90 |
| Equity capital |
339
|
401
|
480 |
| - share capital |
25
|
25
|
27 |
| Employees (average) |
5
|
5
|
5 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
67.9%
|
81.0%
|
84.1% |
| Turnover per employee |
0
|
0
|
0 |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-160.7%
|
-157.0%
|
-133.6% |
| Current ratio |
130.0%
|
175.3%
|
184.4% |
| Return on equity (ROE) |
-236.6%
|
-193.8%
|
-159.0% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
0%
|
0%
|
0% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.